PMID: 9549648Apr 29, 1998Paper

Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures

Journal of Clinical Pharmacology
G M KochakC S Padgett

Abstract

A 56-day pharmacokinetic study of zonisamide was conducted in 24 healthy volunteers. Steady state was achieved in 29 days including two dose escalations, and in an average of 15 days from the last dose adjustment. Twice-daily administration of 200 mg every 12 hours produced a 14% serum level fluctuation at steady state. After once-daily administration of 400 mg, a 27% serum level fluctuation was observed. The terminal-phase half-life after the last dose was 63 to 69 hours, which is consistent with the half-life of 52 to 60 hours found in single-dose studies. This result demonstrates that zonisamide is not an autoinducer. Serum oral clearance of 0.60 to 0.71 L/hr (0.121-0.132 mL/min/kg) was similar to that observed in other multiple-dose studies.

References

Jan 1, 1992·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·D D StiffM A Zemaitis
Feb 1, 1993·Epilepsy Research·I E LeppikJ D Wallace

❮ Previous
Next ❯

Citations

Jul 27, 2001·Neurologic Clinics·S C Schachater
Sep 15, 2006·Seminars in Dialysis·Rubeen K IsraniJeffrey S Berns
May 24, 2013·Drug Design, Development and Therapy·Marco Mula
Sep 1, 2006·Neuropsychiatric Disease and Treatment·Angus A Wilfong, L James Willmore
Feb 14, 2014·Advances in Therapy·Joanna H CoxAndrea E Cavanna
May 28, 2014·Current Treatment Options in Neurology·Nivedita U JerathMark Granner
Apr 24, 2014·Current Treatment Options in Neurology·Batool F KirmaniDaniel Cruz
Dec 22, 2009·Expert Review of Neurotherapeutics·Cecilie Johannessen Landmark, Philip N Patsalos
Apr 25, 2008·Expert Opinion on Drug Metabolism & Toxicology·Sanjeev V Kothare, Joseph Kaleyias
Feb 14, 2012·Advanced Drug Delivery Reviews·Gail D Anderson, Russell P Saneto
Nov 13, 2008·Journal of Veterinary Pharmacology and Therapeutics·D M Boothe, J Perkins
Feb 27, 2007·Epilepsia·Graeme Sills, Martin Brodie
Jul 19, 2008·Experimental Dermatology·Manuela G NeumanLawrence Cohen
Nov 1, 2012·Acta Neurologica Scandinavica. Supplementum·M J BrodieL Giorgi
Sep 17, 2013·The Journal of Obstetrics and Gynaecology Research·Hitoshi AndoAkio Fujimura
Jan 18, 2006·Epilepsy Research·Michel Baulac
Oct 30, 2004·Seizure : the Journal of the British Epilepsy Association·L James Willmore
Nov 28, 2009·Seizure : the Journal of the British Epilepsy Association·Hui Jeen TanRachel Kneen
Oct 30, 2004·Seizure : the Journal of the British Epilepsy Association·Ilo E Leppik
Sep 19, 2002·Seizure : the Journal of the British Epilepsy Association·Katsuaki HiraiNoboru Kumagai
Mar 9, 2010·Thérapie·Marie-Clémence VerdierUNKNOWN le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique
Mar 29, 2002·Journal of Child Neurology·James W Wheless
Jun 30, 2018·Therapeutic Drug Monitoring·Philip N PatsalosDave J Berry
Dec 12, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S Arroyo, G Kramer
Jan 5, 2013·Therapeutic Drug Monitoring·Philip N Patsalos, Dave J Berry
Dec 16, 1998·Therapeutic Drug Monitoring·T Mimaki
Dec 17, 2009·Expert Opinion on Pharmacotherapy·Andreas Schulze-Bonhage
Dec 1, 1998·CNS Drug Reviews·Yoshinobu MasudaMasanao Shimizu
Mar 16, 2001·Expert Opinion on Pharmacotherapy·K K Jain
Mar 5, 2019·Metabolomics : Official Journal of the Metabolomic Society·J C Martínez-ÁvilaA M Borobia
Sep 29, 2020·Frontiers in Neurology·Jingying WuLi Cao

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.